Antonio is Head of the Department of Biochemistry from the Faculty of Medicine (UAM University) and Principal Investigator of the group. For the past years his research has focused on: i) The transcription factor Nrf2 as a new therapeutic target in Parkinson’s and Alzheimer’s disease; ii) The role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases; iii) The pharmacological regulation of autophagy in the brain as a novel therapeutic strategy for neurodegenerative proteinopathies.

Dr. Cuadrado has been awarded several research projects funded by private, local, and
governmental agencies to study the molecular basis of Parkinson’s and Alzheimer’s disease. He has published over 100 primary and review articles, of which more than 50 are related to neuroprotection in preclinical models of Parkinson’s and Alzheimer’s disease. He is grant and fellowship evaluation consultant for Spanish governmental and autonomic agencies. He is advisor of Aclipse One Inc. a subsidiary of Aclipse Therapeutics LLC in Delaware.